,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2013-01-13 23:50:00,"Medical devices major, St. Jude Medical Inc. ( STJ ) released preliminary results for the 2012-fourth quarter.",0.02615254744887352,0.00859854370355606,0.9652489423751831,neutral,0.01755400374531746
1,2013-01-13 23:50:00,"The company will report its financial results on Jan 23, before markets opens.",0.01663479581475258,0.00658607529476285,0.9767791032791138,neutral,0.010048720985651016
2,2013-01-13 23:50:00,"St. Jude expects adjusted earnings for the quarter in the range of 90 cents-92 cents per share, surpassing its earlier guidance of 86 cents-88 cents.",0.9432708024978638,0.024471569806337357,0.032257672399282455,positive,0.9187992215156555
3,2013-01-13 23:50:00,This compared with the Zacks Consensus Estimate of 89 cents for the quarter.,0.4536997377872467,0.4420070946216583,0.10429323464632034,positive,0.011692643165588379
4,2013-01-13 23:50:00,Adjusted earnings exclude one-time item charges of 50 cents-60 cents per share related to restructuring and other corporate activities.,0.01145409606397152,0.050144586712121964,0.9384013414382935,neutral,-0.03869049251079559
5,2013-01-13 23:50:00,Management stated that sales growth and cost reduction measures will lead to the improvement in earnings.,0.9436842203140259,0.016290368512272835,0.04002537950873375,positive,0.9273938536643982
6,2013-01-13 23:50:00,"Total revenues for the quarter, on a constant currency basis, are projected to be $1,372 million, down 1% year over year.",0.016792364418506622,0.9698847532272339,0.01332288607954979,negative,-0.9530923962593079
7,2013-01-13 23:50:00,"The Zacks Consensus Estimate for revenues is $1,370 million.",0.013747545890510082,0.009543357416987419,0.9767091274261475,neutral,0.004204188473522663
8,2013-01-13 23:50:00,"Based on the above projections, revenues from the core Cardiac Rhythm Management (CRM) business declined 6% (5% on a constant currency basis) to $682 million.",0.018452012911438942,0.972647488117218,0.008900430053472519,negative,-0.954195499420166
9,2013-01-13 23:50:00,"Within CRM, Implantable cardiac defibrillators (ICD) revenues were down 3% at $422 million.",0.01633266545832157,0.9708647131919861,0.012802612036466599,negative,-0.9545320272445679
10,2013-01-13 23:50:00,This segment continues to be plagued by the Durata lead issues.,0.02550395391881466,0.9018441438674927,0.0726519227027893,negative,-0.8763402104377747
11,2013-01-13 23:50:00,Pacemaker revenues declined 11% to roughly $260 million.,0.015810668468475342,0.9721878170967102,0.012001481838524342,negative,-0.9563771486282349
12,2013-01-13 23:50:00,"Neuromodulation revenues decreased 7%, (down 6% in constant currency) year over year to $113 million.",0.01716836914420128,0.9737561345100403,0.009075508452951908,negative,-0.9565877914428711
13,2013-01-13 23:50:00,Revenues from St. Jude's Cardiovascular segment inched down 1% (up 1% in constant currency) to $338 million.,0.018286440521478653,0.9711010456085205,0.010612459853291512,negative,-0.9528145790100098
14,2013-01-13 23:50:00,"Within Cardiovascular segment, structural heart devices revenues increased 1% to $152 million but the same from vascular offerings dipped 2% to $186 million.",0.9539046883583069,0.02347269281744957,0.022622641175985336,positive,0.9304320216178894
15,2013-01-13 23:50:00,"However, on a positive note, Atrial Fibrillation (AF) revenues climbed 10% (up 11% in constant currency) to $239 million in the quarter.",0.9588510394096375,0.021051323041319847,0.020097622647881508,positive,0.9377996921539307
16,2013-01-13 23:50:00,"St. Jude, with a market cap of $11.80 billion, is a leading medical devices manufacturer maintaining a solid rate of growth over the past decade.",0.9271530508995056,0.013533389195799828,0.0593135841190815,positive,0.9136196374893188
17,2013-01-13 23:50:00,We are impressed by the company's efforts in leveraging its margins by undertaking various restructuring initiatives and controlling expenses.,0.8798370361328125,0.011669949628412724,0.10849295556545258,positive,0.8681671023368835
18,2013-01-13 23:50:00,"However, St. Jude's ICD business is facing operational headwinds concerning the Durata leads, which is affecting its top-line growth.",0.020948335528373718,0.9604566097259521,0.018595052883028984,negative,-0.9395082592964172
19,2013-01-13 23:50:00,This might lead its competitors in the CRM space such as Medtronic Inc. ( MDT ) and Boston Scientific Corporation ( BSX ) gain market share.,0.9422875046730042,0.01746475137770176,0.04024772718548775,positive,0.9248227477073669
20,2013-01-13 23:50:00,"St. Jude currently carries a Zacks Rank #3 (Hold), which complements our Neutral recommendation on the stock for the long term.",0.169444739818573,0.018180090934038162,0.8123751878738403,neutral,0.15126465260982513
21,2013-01-13 23:50:00,To read this article on Zacks.com click here.,0.01796119473874569,0.019245078787207603,0.9627937078475952,neutral,-0.001283884048461914
22,2013-01-13 23:50:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
